Prelude PRLD 深 沪
等待开盘 11-01 09:30:00 美东时间
1.59
+0.020
+1.27%
华盛通- 最 高1.64
- 今 开1.56
- 成交量 11.14万股
- 最 低 1.51
- 昨 收 1.57
- 总市值 8999.45万
- 52周最高 1.91
- 市盈率 静 --
- 换手率 0.20%
- 52周最低 0.6101
- 委 比 65.29%
- 总股本 5660.03万
- 历史最高 95.375
- 量 比 0.59
- 振 幅 8.28%
- 历史最低 0.6101
- 每 手 1
- 风险率 0.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Prelude Therapeutics Appoints Katina Dorton to Board
Prelude Therapeutics ( ($PRLD) ) has provided an update. On October 17, 2025, P...
10-17 19:57
Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors
Prelude Therapeutics announced the appointment of Katina Dorton to its Board of Directors. With over 30 years of experience in healthcare and life sciences, Dorton brings significant leadership and financial expertise. She recently served as Chief Financial Officer at NodThera and previously oversaw finance at Repare Therapeutics, AVROBIO, and Immatics. Dorton also has extensive experience in investment banking with Morgan Stanley and Neuberger B...
10-17 11:30
美股大行评级 | 升至450美元，瑞穗上调特斯拉目标价；富国银行上调CoreWeave至"超配"，目标价升至170美元
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从44美元升至84美元；Oppenheimer：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至80美元
09-24 10:23
HC Wainwright & Co. Reiterates Buy on Prelude Therapeutics, Maintains $5 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Prelude Therapeutics (NASDAQ:PRLD) with a Buy and maintains $5 price target.
09-23 19:08
Prelude Therapeutics Regains Nasdaq Compliance
The latest update is out from Prelude Therapeutics ( ($PRLD) ). Prelude Therape...
09-19 19:58
Prelude Therapeutics shares are trading lower. The company reported Q2 financial results.
Prelude Therapeutics shares are trading lower. The company reported Q2 financia...
08-16 00:01
Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Prelude Therapeutics reported Q2 2025 financial results with $77.3M in cash, funding operations into Q2 2026. R&D expenses decreased to $25.8M, G&A to $6.4M, with net loss of $31.2M. Company advanced PRT7732 (oral SMARCA2 degrader) to 7th dose cohort and paused PRT3789 IV program. KAT6A degrader IND on track for H1 2026. Preclinical data highlighted precision ADCs and mCALR-targeted therapies.
08-14 11:00
Deal Dispatch: Performance Food Group And Claire's Lead A Week Of Big Auctions, Retail Woes
Performance Food rejects offer; Lufthansa drops Air Europa bid; NFL inks deal with ESPN; Claire's files bankruptcy amid retail struggles.
08-09 04:02
